Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-003367
Filing Date
2025-08-05
Accepted
2025-08-05 16:58:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10645
2 JOINT FILING AGREEMENT p25-1729exhibit99_1.htm EX-99.1 5652
  Complete submission text file 0000902664-25-003367.txt   18065
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Subject) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89290 | Film No.: 251185927
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G